Every 10-Q that Arcadia Biosciences, Inc. (RKDA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RKDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RKDA filings page.
Arcadia Biosciences, Inc. reported Q2 2026 product revenues of $1.4 million, essentially flat versus Q2 2025, all from Zola coconut water. For the first six months of 2026, revenues were $2.5 million, down modestly from the prior-year period.
The company generated a Q2 2026 net loss attributable to common stockholders of $6.3 million and a year‑to‑date loss of $10.7 million, driven by a $5.4 million valuation loss on the June 2026 PIPE financing, a $2.9 million loss on the January 2026 inducement offer, unrealized losses on AFII shares, and issuance and offering costs. Selling, general and administrative expenses declined sharply year over year, reflecting lower M&A and employee costs.
At June 30, 2026, cash and cash equivalents were $4.2 million, total assets $5.9 million, and stockholders’ equity $0.6 million, with $3.6 million of warrant and option liabilities. Management states that existing cash will not meet anticipated needs for at least 12 months, raising substantial doubt about the ability to continue as a going concern absent additional financing or asset sales.
Arcadia Biosciences reported a sharp swing to loss in the quarter ended March 31, 2026, alongside serious liquidity pressure and a going concern warning. Product revenue from Zola coconut water was $1.1 million, down 8% from $1.2 million a year earlier, mainly because a prior-year revenue reserve release did not recur.
The company posted a net loss attributable to common stockholders of $4.4 million, versus net income of $2.6 million in the prior-year quarter. Results were heavily affected by a $2.9 million Loss on January 2026 Inducement Offer tied to modified warrants and options, and a $1.5 million unrealized loss on AFII shares received from the GoodWheat sale. These were partly offset by a $1.2 million non‑cash gain from remeasuring warrant and option liabilities.
Cash and cash equivalents were $1.0 million as of March 31, 2026, with working capital of $3.8 million. Management states this cash will not cover anticipated needs for at least 12 months, leading to substantial doubt about the company’s ability to continue as a going concern. Above Food’s default on a $4.0 million remaining promissory note and uncertainty around monetizing AFII shares further strain funding, and Arcadia may need additional equity, debt, asset sales, or strategic alternatives to continue operating.
Arcadia Biosciences (RKDA) filed its Q3 2025 report, showing modest product revenue and a small quarterly profit driven by non-operating gains. Revenue was $1.3 million, down from $1.5 million a year ago. Operating loss narrowed to $1.2 million, while net income from continuing operations was $0.9 million, or $0.62 per diluted share, helped by other income and a reduction in warrant and option liabilities.
Liquidity remains tight. Cash and cash equivalents were $1.1 million as of September 30, 2025, with $4.8 million of short-term investments. Management states there is “substantial doubt” about the company’s ability to continue as a going concern based on current cash needs. Net cash used in operations was $3.9 million for the first nine months of 2025.
During 2025, the company recorded a $4.7 million credit loss tied to a note from the 2024 GoodWheat sale and received approximately 2.7 million shares of Above Food Ingredients, Inc., contributing to other income. Arcadia also recorded a $0.8 million gain from changes in fair value of warrant and option liabilities in the quarter. Shares outstanding were 1,373,120 as of October 31, 2025.
Arcadia Biosciences (RKDA) disclosed several material corporate and accounting developments in its Form 10-Q. The company amended an Exchange Agreement and filed a Form S-4 related to an equity issuance, extending the agreements termination date to August 15, 2025. As of June 30, 2025 the company had 150,000,000 shares authorized and 1,367,040 shares issued and outstanding (1,364,940 at December 31, 2024).
The company treated the sale of its GoodWheat business as a discontinued operation under ASC 205-20, recognizing a $1,500 loss in the second quarter of 2024. A contingent liability tied to prior Anawah technology obligations of $2.0 million was eliminated as of June 30, 2025 after program abandonments and transfers. The company recorded an additional right-of-use asset and lease liability of $86,000 related to a lease renewal and later terminated that facility lease effective July 2024.
Equity plans changed: the 2015 Plan terminated for future awards in May 2025; 338,341 shares remained reserved under the 2015 Plan as of June 30, 2025. The company faces a Proposition 65-related BPA lawsuit amended May 23, 2025, and answered the complaint on July 22, 2025, denying liability. Managements CODM evaluates performance using consolidated net (loss) income.